Every year, nearly 11,000 Americans die of acute myeloid leukemia (AML), a blood cancer that affects mainly older adults. While most patients initially respond to chemotherapy, more than half of those who respond will eventually ...
Apr 25, 2019
0
2
Three children Alejandro Gutierrez, MD, treated for leukemia during his fellowship at Boston Children's Hospital still haunt him more than a decade later. One 15-year-old boy died from the toxicity of the drugs he was given; ...
Apr 16, 2019
0
3
There could be new treatments on the horizon for diffuse intrinsic pontine glioma, or DIPG, a devastating form of brain cancer that afflicts young children and is currently incurable. Recent experiments in animal models of ...
Apr 4, 2019
0
664
The prognosis for older patients with acute myeloid leukemia (AML) is poor: very few achieve remission and for those that don't the option is largely palliative.
Mar 21, 2019
0
5
In a study published in The Oncologist, physicians treating certain cancers who consistently received payments from a cancer drug's manufacturer were more likely to prescribe that drug over alternative treatments.
Feb 6, 2019
0
0
Many new anti-cancer drugs inhibit proteins that are essential for the proliferation of cancer cells. One example is ibrutinib, an innovative therapy for chronic lymphocytic leukemia first approved in 2014. Chronic lymphocytic ...
Jan 29, 2019
0
18
Researchers have been struggling for years to find a treatment for patients who have a recurrence of acute myeloid leukemia (AML), an aggressive blood cancer that is one of the most lethal cancers. About 19,520 news cases ...
Jan 28, 2019
0
0
Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).
Dec 8, 2018
0
138
Older patients with acute myeloid leukemia (AML) often aren't healthy enough to receive intensive chemotherapy, and gentler treatments aren't very effective in treating this aggressive blood cancer.
Nov 29, 2018
0
4
Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients ...
Nov 28, 2018
0
72
